No Data
No Data
Sino Biopharmaceutical Gets Selected by S&P Global, FTSE4Good Index for ESG Practices
Sino Biopharmaceutical (HKG:1177) was selected for the second year in a row by the S&P Global Sustainability Yearbook (China Edition) 2024 for its performance in the S&P Global Corporate
Sino Biopharm (01177.HK): ESG performance recognized by S&P Global and FTSE Russell.
Sino Biopharm (01177.HK) announced on July 19th that the group has been recognized by multiple global sustainable development authorities, such as S&P Global and FTSE Russell, based on its continuous and stable environmental, social and corporate governance (ESG) performance.
Sino Biopharmaceutical's Phase-3 Trial of Breast Cancer Drug Reaches Primary Endpoint
Sino Biopharmaceutical's (HKG:1177) interim analysis of a phase III clinical trial of its Culmerciclib capsule combined with the Fulvestrant injection has met the default primary endpoints, a
Sino Biopharm (01177) under the Hong Kong stock connect program: Phase III clinical trials related to breast cancer treatment achieve the predetermined primary endpoint.
Sinobiopharm (01177) announced that the phase III clinical trial (NCT05375461) of type 1 innovative drug Culmerciclib (TQB3616) developed by the group and combined with fluvisinque injection for the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer that has been treated with endocrine therapy in the past has completed mid-term analysis and has achieved the preset primary endpoint after being reviewed by the Independent Data Monitoring Committee (IDMC). The research results will be published in academic journals or major academic conferences.
Sino Biopharm (01177.HK): The new drug application for Class 1 innovative drug Culmerciclib (TQB3616) has been accepted for listing.
Sino Biopharm (01177.HK) announced that the Phase III clinical trial (NCT05375461) of the class 1 innovative drug Culmerciclib (TQB3616) developed by the group, combined with Fluvisumab injection for the treatment of Hormone Receptor (HR)-positive and Human Epidermal Growth Factor Receptor 2 (HER2)-negative locally advanced or metastatic breast cancer previously treated with endocrine therapy, has completed mid-term analysis and achieved the preset primary endpoint after being reviewed by the Independent Data Monitoring Committee (IDMC). The research results will be published in academic journals or major publications.
Express News | Sino Biopharmaceutical - Acceptance by National Medical Products Administration
No Data